Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab effects on coronary atherosclerosis after acute myocardial infarction
2017-001502-15Phase 3Completed
- Sponsor
- Insel Gruppe
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI), coronary arteriosclerosis and hypercholesterolemia comparing Alirocumab plus high-intensity statin therapy with Placebo plus high-intensity statin therapy (2 arms). Primary endpoint: Change in percent atheroma volume. Started Sep 2017; status: completed.
02
Drugs
alirocumab
03
Conditions
myocardial infarction (MI)coronary arteriosclerosishypercholesterolemia
Beyond the preview
Go deeper on 2017-001502-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001502-15.